Radiopharmaceutical for Nuclear Medicine Research:CAGR of 8.5% during the forecast period

Radiopharmaceutical for Nuclear Medicine Market Summary

Radiopharmaceuticals refer to radioactive isotopes and their pharmaceutical formulations used in the medical field for diagnosis, therapy, and research. These products utilize the radiation emitted by radionuclides to enable functional imaging of organs and tissues (e.g., via PET or SPECT) or to deliver localized radiotherapy (such as brachytherapy or targeted radiopharmaceutical therapy). Common medical nuclides include Technetium-99m, Iodine-131, Iodine-125, Fluorine-18, Gallium-68, Yttrium-90, Thulium-161, and Lutetium-177, which are widely applied in oncology, cardiology, neurology, and other clinical areas.

The global Radiopharmaceuticals market is experiencing steady growth driven by increasing demand for early and accurate diagnosis, especially in oncology, cardiology, and neurology. The rising global incidence of cancer and chronic diseases has led to broader clinical adoption of nuclear medicine imaging technologies such as PET and SPECT, which rely heavily on radiopharmaceuticals like ^18F-FDG, ^68Ga-PSMA, and ^123I-FP-CIT. Technological advancements in radiochemistry and radiolabelling, along with the growing application of theranostics (the integration of diagnosis and therapy), are creating strong momentum for the development and use of dual-purpose radiopharmaceuticals like [^68Ga]/[^177Lu]-DOTATATE. Government initiatives to improve medical infrastructure, establish local radioisotope production facilities, and fast-track the regulatory approval of nuclear medicine products are further accelerating market growth, particularly in emerging economies. Additionally, increasing collaboration between academic institutions, pharmaceutical companies, and diagnostic imaging providers is expanding research pipelines and commercial readiness of novel nuclide-based agents.

Despite these positive trends, the Radiopharmaceuticals market faces several notable challenges. One of the most critical issues is the short half-life of many radionuclides, which necessitates localized production and just-in-time distribution, often through highly regulated cold-chain logistics systems. This creates logistical barriers, particularly in less-developed or remote regions lacking production facilities or PET cyclotrons. Moreover, the global supply of key isotopes like Molybdenum-99, Iodine-123, and Lutetium-177 is still heavily reliant on aging nuclear reactors, making the supply chain vulnerable to geopolitical disruptions and scheduled reactor shutdowns. Regulatory complexity and stringent safety requirements around the handling, transport, and use of radioactive materials increase compliance costs and lengthen product development timelines. Lastly, there is a shortage of skilled professionals in nuclear medicine, limited reimbursement frameworks in many countries, and slow integration of advanced nuclear techniques into routine clinical practice, all of which constrain the broader adoption of Radiopharmaceuticals. Addressing these issues will be essential for realizing the full potential of nuclear medicine in global healthcare.

According to the new market research report "Global Radiopharmaceutical for Nuclear Medicine Market Report 2026-2032", published by QYResearch, the global Radiopharmaceutical for Nuclear Medicine market size is projected to reach USD 19.73 billion by 2032, at a CAGR of 8.5% during the forecast period.

Figure00001. Global Radiopharmaceutical for Nuclear Medicine Market Size (US$ Million), 2021-2032

Radiopharmaceutical for Nuclear Medicine

Above data is based on report from QYResearch: Global Radiopharmaceutical for Nuclear Medicine Market Report 2026-2032 (published in 2025). If you need the latest data, plaese contact QYResearch.

Figure00002. Global Radiopharmaceutical for Nuclear Medicine Top 17 Players Ranking and Market Share (Ranking is based on the revenue of 2025, continually updated)

Radiopharmaceutical for Nuclear Medicine

Above data is based on report from QYResearch: Global Radiopharmaceutical for Nuclear Medicine Market Report 2026-2032 (published in 2025). If you need the latest data, plaese contact QYResearch.

According to QYResearch Top Players Research Center, the global key manufacturers of Radiopharmaceutical for Nuclear Medicine include Novartis, Cardinal Health, Lantheus Medical Imaging, Curium Pharma, China Isotope & Radiation, etc. In 2025, the global top five players had a share approximately 63.0% in terms of revenue.

Figure00003. Radiopharmaceutical for Nuclear Medicine, Global Market Size, Split by Product Segment

Radiopharmaceutical for Nuclear Medicine

Based on or includes research from QYResearch: Global Radiopharmaceutical for Nuclear Medicine Market Report 2026-2032.

In terms of product type, currently Diagnosis Nuclear Medicine is the largest segment, hold a share of 56.4%.

About The Authors

Zhang Xiao - Lead Author

Email: zhangxiao@qyresearch.com

Zhang Xiao is a market senior analyst specializing in medical device, pharma, Lab consumable. Zhang Xiao has 8 years' experience in medical device and pharma market analysis, and focuses on medical device and consumables (imaging equipment, medical consumables, wearable medical equipment, medical robots, home care equipment, dental equipment, implant equipment, operating room equipment, in vitro diagnostics, etc.) and drugs (API, finished drugs, patented drugs, blood products , vaccines, etc.) . She is engaged in the development of technology and market reports and is also involved in custom projects.

About QYResearch

QYResearch founded in California, USA in 2007.It is a leading global market research and consulting company. With over 17 years' experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting (data is widely cited in prospectuses, annual reports and presentations), industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability. Up to now, we have cooperated with more than 60,000 clients across five continents. Let's work closely with you and build a bold and better future.

QYResearch is a world-renowned large-scale consulting company. The industry covers various high-tech industry chain market segments, spanning the semiconductor industry chain (semiconductor equipment and parts, semiconductor materials, ICs, Foundry, packaging and testing, discrete devices, sensors, optoelectronic devices), photovoltaic industry chain (equipment, cells, modules, auxiliary material brackets, inverters, power station terminals), new energy automobile industry chain (batteries and materials, auto parts, batteries, motors, electronic control, automotive semiconductors, etc.), communication industry chain (communication system equipment, terminal equipment, electronic components, RF front-end, optical modules, 4G/5G/6G, broadband, IoT, digital economy, AI), advanced materials industry Chain (metal materials, polymer materials, ceramic materials, nano materials, etc.), machinery manufacturing industry chain (CNC machine tools, construction machinery, electrical machinery, 3C automation, industrial robots, lasers, industrial control, drones), food, beverages and pharmaceuticals, medical equipment, agriculture, etc.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

About Us:
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.

This release was published on openPR.